// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

How often is a single therapeutic aspiration sufficient to manage a malignant pleural effusion and does oncological treatment have an impact on this?

Rachel Mercer - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Technical limitation of semi-automated volumetric analysis using CT in patients with Malignant Pleural Mesothelioma

Andrew C Kidd - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

N/A

An assessment of treatment decisions and patient outcomes in Pleural Service users based on age and performance status, at the Western General Hospital, in Edinburgh

Alex Forster - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Case Series: Non-resolving pneumothorax – an early presentation of mesothelioma

Alexander Taylor - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Malignant pleural mesothelioma

N/A

LENT score - useful clinical tool?

Bavithra Vijayakumar - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Three Year Retrospective analysis of Pleural Procedure Services

Narendrababu Rampura Chinnappa - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Lymphocytic Pleural Effusions: Aetiology and Frequency in a UK District General Hospital

Damian Dooey - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Systematic review of the management of Solitary Fibrous Tumours of the Pleura (SFTP)

Rachel Mercer - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patient derived pleural mesothelioma cell lines, can be used as tools, to guide patient stratification

Nikolaos I. Kanellakis - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

N/A

Cytology positive pleural aspirations: sufficient to guide treatment?

Rebecca Varatharajah - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung?

Gillian Shepherd - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Negative predictive value of pleural fluid cytology in patients with a background of cancer

Olalla Castro Anon - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Half-dose thrombolysis for intermediate-high risk pulmonary embolism: Case series from a London hospital

Rishi Gupta - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

N/A

Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes

Natalie Hill - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

Sildenafil citrate

Incorporating age adjusted d-dimer limit in place of differential cut-off in YEARS algorithm. Does it help to reduce CTPA burden?

Ahsan Zahid - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cataract 6, multiple types

N/A

Streamlining diagnostic work-up of pulmonary embolism: Comparing YEARS algorithm with original and simplified Well’s scores

Ahsan Zahid - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pulmonary embolism

N/A

Can implementation of the pulmonary embolism rule-out criteria (PERC) safely reduce D-dimer and CTPA requests in a two-tier Wells model?

Hui Li Ang - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pulmonary embolism

N/A

Outpatient management of PE

Bavithra Vijayakumar - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cataract 6, multiple types

N/A

Adherence to standard diagnostic algorithms for pulmonary embolus in a UK district general hospital

James Heggie - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE)

William Thomas - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic thromboembolic pulmonary hypertension

N/A

Copyright © 2026. QuantiNova All rights reserved